Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

It appears some investors may be coming round to the thinking of Ken Griffin, the billionaire founder of hedge fund Citadel, who recently warned that the "uncertainty and chaos" created by President ...

Brand collaborations remain a popular tactic for challenger brands to reach new audiences. Bubble Skincare and Touchland will ...

Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...

Stocks in Focus. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against ...

Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...